Literature DB >> 24069724

WHO Expert Consultation on Rabies. Second report.

.   

Abstract

Although there is debate about the estimated health burden of rabies, the estimates of direct mortality and the DALYs due to rabies are among the highest of the neglected tropical diseases. Poor surveillance, underreporting in many developing countries, frequent misdiagnosis of rabies, and an absence of coordination among all the sectors involved are likely to lead to underestimation of the scale of the disease It is clear, however, that rabies disproportionately affects poor rural communities, and particularly children. Most of the expenditure for postexposure prophylaxis is borne by those who can least afford it. As a result of growing dog and human populations, the burden of human deaths from rabies and the economic costs will continue to escalate in the absence of concerted efforts and investment for control. Since the first WHO Expert Consultation on Rabies in 2004, WHO and its network of collaborating centres on rabies, specialized national institutions, members of the WHO Expert Advisory Panel on Rabies and partners such as the Gates Foundation, the Global Alliance for Rabies Control and the Partnership for Rabies Prevention, have been advocating the feasibility of rabies elimination regionally and globally and promoting research into sustainable cost-effective strategies. Those joint efforts have begun to break the cycle of rabies neglect, and rabies is becoming recognized as a priority for investment. This Consultation concluded that human dog-transmitted rabies is readily amenable to control, regional elimination in the medium- term and even global elimination in the long-term. A resolution on major neglected tropical diseases, including rabies, prepared for submission to the World Health Assembly in May 2013 aims at securing Member States' commitment to the control, elimination or eradication of these diseases. Endorsement of the resolution would open the door for exciting advances in rabies prevention and control.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24069724

Source DB:  PubMed          Journal:  World Health Organ Tech Rep Ser        ISSN: 0512-3054


  133 in total

1.  Effect of Corticosteroids on RVNA production of a patient with acute disseminated encephalomyelitis following rabies vaccination as well as administration of HRIG.

Authors:  Jun Peng; Li Chen; Zheng-Gang Zhu; Ze-Rong Zhu; Quan Hu; Yuan Fang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Prioritization of capacities for the elimination of dog-mediated human rabies in the Americas: building the framework.

Authors:  Victor J Del Rio Vilas; Adamelia Burgeño; Gilberto Montibeller; Alfonso Clavijo; Marco Antonio Vigilato; Ottorino Cosivi
Journal:  Pathog Glob Health       Date:  2013-10       Impact factor: 2.894

3.  Rabies post-exposure prophylaxis for a male with severe Henoch Schönlein purpura following rabies vaccination.

Authors:  Zheng-Gang Zhu; Yi Zheng; Sha Lu; Quan Hu; Yuan Fang
Journal:  Hum Vaccin Immunother       Date:  2018-06-29       Impact factor: 3.452

4.  Dog Bite Injuries in the Head and Neck Region: A 20-Year Review.

Authors:  Frederik Piccart; Jakob Titiaan Dormaar; Ruxandra Coropciuc; Joseph Schoenaers; Michel Bila; Constantinus Politis
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2018-06-22

5.  Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above.

Authors:  Jing Wang; FengJi Luo; ZiJian Feng; Li Li; YunHua Bai; Xing Ai; JianXin Ma; Zheng Zhang; NianMin Shi
Journal:  Hum Vaccin Immunother       Date:  2017-01-02       Impact factor: 3.452

6.  Healthcare demand in response to rabies elimination campaigns in Latin America.

Authors:  Jonathan Yoder; Elisabeth Younce; Felix Lankester; Guy H Palmer
Journal:  PLoS Negl Trop Dis       Date:  2019-09-26

7.  A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.

Authors:  Jingchen Ma; Hongchang Wang; Jun Li; Likuan Chang; Yun Xie; Zhonglin Liu; Yuliang Zhao; Claudius Malerczyk; Malerczyk Claudius
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases.

Authors:  Ashwath Narayana; Aravind Manoharan; Madhusudana Shampur Narayan; Sudarshan Mysore Kalappa; Gangaboraiah Biligumba; Ravish Haradanahalli; Ashwini Manoor Anand
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

9.  Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.

Authors:  RongCheng Li; YanPing Li; ShuQing Wen; HuiChun Wen; Yi Nong; Zhaojun Mo; Fang Xie; Michele Pellegrini
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects.

Authors:  Nianmin Shi; Yibin Zhang; Huizhen Zheng; Zhenggang Zhu; Dingming Wang; Sihai Li; Yuhua Li; Liqing Yang; Junnan Zhang; Yunhua Bai; Qiang Lu; Zheng Zhang; Fengji Luo; Chun Yu; Li Li
Journal:  Hum Vaccin Immunother       Date:  2017-01-25       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.